Allele Advances Clinical-Grade iPSC Bioprinting Through ARPA-H PRINT Program
Allele Biotechnology & Pharmaceuticals began working on developing all cell types from autologous iPSC with funding support from the Advanced Research Projects Agency for Health (ARPA-H) under the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program in collaboration with UC San Diego. The goal of this ambitious, “moonshot” program under ARPA-H is to advance 3D bioprinting of functional human liver tissue derived from patient-iPSC thereby avoiding the need for an immune suppressor after transplantation. When successful, this program will ease donor-organ shortages and bring regenerative medicine to a new level.
Allele will leverage its cGMP iPSC platform to produce all essential human liver cell types needed for bioprinting a liver organ, including the vasculature and bile ducts, and will manufacture them at a quality and scale that supports clinical translation of the final product. Our partners at UCSD bring world-leading bioprinting, imaging, and translational expertise that are key to the success of this endeavor.
Along with these developments, Allele announces creative solutions to democratize access to cGMP iPSC lines (off-the-shelf, bespoke and custom options) for therapeutic developers. Alongside more conventional licensing agreements we have developed with more mature pharmaceutical and biotech companies over the past 10 years, we now offer new flexible, stage-appropriate pathways, working with emerging innovators with access to high quality GMP starting iPSC lines and other materials sooner and more efficiently.
Please feel free to contact us if you’d like additional information. We’d be happy to share details on available lines, documentation packages, and typical timelines.
To read the full announcement click here:
